GET DAILY SIGNALSSurrozen (SRZN): Q3 2026 Earnings Outlook and What Matters Most
Key Takeaways
- Surrozen is expected to report its third-quarter 2026 results (the quarter ended September 30, 2026) in November 2026, with analysts modeling a net loss of roughly $1.10 per share on revenue near $475,000.
- Consensus implies a sharp year-over-year revenue decline from $983,000 in Q3 2025, a period that benefited from collaboration milestone recognition.
- The company's most recent report surprised to the upside: a $0.41 per-share loss beat the $1.29 estimate, and revenue of $5.0 million was driven largely by Boehringer Ingelheim milestone payments.
- Investors will focus on cash runway, research and development spending, and clinical progress on the lead Wnt-pathway candidate SZN-8141.
- Surrozen has topped consensus EPS estimates in only three of its last eight quarters, so a clean beat is far from assured.
- For more on Surrozen's Major News, Today's Price Move, Price Targets, and Forecast, explore Tickeron's dedicated pages.
Why This Quarter's Report Matters
Surrozen's third-quarter results will help clarify whether the revenue spike in the second quarter was a one-off milestone or the beginning of something more consistent. As a clinical-stage biotechnology company centered on the Wnt signaling pathway, Surrozen remains largely pre-revenue outside of collaboration and milestone payments. In Q2 2026, revenue reached $5.0 million—well above the roughly $0.47 million consensus—thanks to milestone payments from the Boehringer Ingelheim partnership. With operating costs still high as SZN-8141 moves through development, investors are tracking cash burn and the balance sheet alongside the top line. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Analyst Projections for Q3 2026
Analysts expect Surrozen to report a net loss of approximately $1.10 per share for the third quarter of 2026, with consensus revenue near $475,000. That compares with a loss of $8.36 per share on revenue of $983,000 in the same quarter a year earlier. The modeled revenue decline of roughly 52% year over year underscores how much the prior-year period relied on collaboration milestone income.
For context, the most recent quarter (Q2 2026) delivered a $0.41 per-share loss against a $1.29 consensus estimate, while revenue of $5.0 million far exceeded the $0.47 million forecast. That beat was driven by milestone payments under the Boehringer Ingelheim collaboration. Historically, Surrozen has exceeded consensus EPS estimates in only three of its last eight quarters, which highlights the variability around these releases. Investors should view the current consensus as a baseline rather than an exact target, given the company's limited revenue visibility. From what I see, this pattern suggests treating each quarter's numbers with some caution.
Market Sentiment Heading Into the Report
Sentiment ahead of the third-quarter report appears measured but attentive. Surrozen's shares have shown notable volatility around recent earnings, and the second-quarter revenue beat showed how quickly milestone-driven income can shift perceptions. Because the Q2 top-line surge was tied to a specific event, the market is likely to look past any headline revenue decline and focus instead on operating expenses, cash position, and clinical updates.
Key risks include the chance of a wider-than-expected net loss, higher R&D spending, or signs that additional financing may be required. A narrower loss or new collaboration income could support sentiment, while a miss or weaker balance-sheet details could weigh on the stock.
What to Watch in the Quarters Ahead
Several elements will shape how investors interpret Surrozen's path forward. The sustainability of collaboration revenue stands out first. The second-quarter top-line beat came from milestone payments tied to the Boehringer Ingelheim partnership. A drop back to a few hundred thousand dollars in the third quarter would confirm the Q2 spike was non-recurring, while any fresh milestone or collaboration income would point to a stronger revenue pipeline than currently modeled.
Next, track research and development expense along with the rate of cash use. As SZN-8141 advances through clinical development, spending is expected to stay elevated, and the cash position will indicate whether additional financing could be needed. Management commentary on cash runway and any updates to operating expense guidance will be worth noting.
Finally, clinical milestones for SZN-8141 and progress across the broader Wnt-modulating pipeline remain the main long-term drivers. Updates on enrollment, data timing, or regulatory interactions could matter more than any single quarter's financials. Broader biotech sentiment and financing conditions will also continue to influence valuation for a pre-revenue clinical-stage company, making balance-sheet management as important as clinical execution. I'm watching this closely as the story unfolds.
Refining Research with Tickeron Tools
In preparing for earnings season, I often turn to Tickeron’s AI Screener to quickly filter biotech names by technical patterns, fundamentals, and volatility metrics. It helps surface comparable ideas without spending hours on manual screens and gives a clearer sense of how Surrozen fits within the sector. This kind of systematic check has become a regular part of my process when volatility around reports is expected.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SRZN in upward trend: price rose above 50-day moving average on October 19, 2026
SRZN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 47 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on SRZN as a result. In 70 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for SRZN just turned positive on October 27, 2026. Looking at past instances where SRZN's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +9.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRZN advanced for three days, in 247 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for SRZN moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 25 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.666) is normal, around the industry mean (3.482). P/E Ratio (-0.774) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.837) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SRZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement